Insider Selling: Alto Neuroscience (NYSE:ANRO) COO Sells $56,429.28 in Stock

Alto Neuroscience logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alto Neuroscience COO Jr. Michael Conick Hanley sold 2,104 shares for $56,429 at an average price of $26.82, reducing his holdings by 10.61% to 17,729 shares.
  • Hanley also sold 70,000 shares for $1.94 million on November 16 and 2,896 shares for $76,686 on November 18.
  • Alto reported a quarterly loss of $0.54 per share, beating analysts’ $0.67 loss estimate. Analysts’ consensus rating is “Moderate Buy,” with a $37.88 average price target.
  • Five stocks we like better than Alto Neuroscience.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) COO Jr. Michael Conick Hanley sold 2,104 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $26.82, for a total value of $56,429.28. Following the completion of the transaction, the chief operating officer owned 17,729 shares in the company, valued at $475,491.78. The trade was a 10.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jr. Michael Conick Hanley also recently made the following trade(s):

  • On Wednesday, November 18th, Jr. Michael Conick Hanley sold 2,896 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.48, for a total transaction of $76,686.08.
  • On Monday, November 16th, Jr. Michael Conick Hanley sold 70,000 shares of Alto Neuroscience stock. The stock was sold at an average price of $27.68, for a total transaction of $1,937,600.00.

Alto Neuroscience Trading Up 3.4%

Shares of NYSE ANRO traded up $0.85 during mid-day trading on Wednesday, reaching $25.77. The company's stock had a trading volume of 986,145 shares, compared to its average volume of 597,641. The stock has a 50-day moving average of $25.83 and a two-hundred day moving average of $24.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.12 and a quick ratio of 18.12. Alto Neuroscience, Inc. has a 1-year low of $12.51 and a 1-year high of $37.48.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.13. On average, research analysts forecast that Alto Neuroscience, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Zacks Research upgraded shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Wedbush boosted their target price on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. BTIG Research reaffirmed a "buy" rating and issued a $37.00 price target on shares of Alto Neuroscience in a report on Wednesday, November 11th. Finally, Wall Street Zen downgraded Alto Neuroscience from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.88.

View Our Latest Stock Analysis on ANRO

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds have recently modified their holdings of ANRO. Sterling Capital Management LLC raised its stake in Alto Neuroscience by 1,045.7% during the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company's stock worth $27,000 after purchasing an additional 962 shares during the period. Farther Finance Advisors LLC boosted its holdings in Alto Neuroscience by 48,581.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company's stock valued at $137,000 after purchasing an additional 5,344 shares during the last quarter. GK Wealth Management LLC purchased a new stake in shares of Alto Neuroscience in the 2nd quarter valued at approximately $226,000. Empowered Funds LLC acquired a new stake in shares of Alto Neuroscience during the 3rd quarter worth approximately $299,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Alto Neuroscience during the 1st quarter valued at approximately $534,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alto Neuroscience Right Now?

Before you consider Alto Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.

While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines